A Phase 1 trial of iron metabolism-targeting oral gallium maltolate in recurrent and refractory glioblastoma
Clicks: 1
ID: 316370
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #55 of 103 articles by views in Neuro-Oncology Advances
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Gallium maltolate is an oral compound that disrupts iron-dependent glioblastoma (GBM) growth and prolongs survival in animal models. This Phase 1 trial of oral gallium maltolate in patients with recurrent GBM was conducted to assess toxicity, determine a recommended Phase 2 dose (RP2D), and seek signals of tumor response. Methods Using a 3 + 3 dose-escalation design with 5 drug dose levels of oral gallium maltolate (500—2,500 mg daily), 24 patients received a minimum of one 4-week cycle to assess toxicity, and 22 patients of these patients received a minimum of 2 cycles to assess tumor response. Patients with stable disease on MRI at 8 weeks continued treatment until progression. Results Grade 1 or 2 adverse effects of diarrhea, anorexia, nausea, and fatigue occurred in 24 patients. The RP2D was determined by considering diarrhea requiring treatment and serum gallium levels that plateaued at doses of 2,000—2,500 mg/day. ALT elevation occurred in 1 patient each on 1,000 and 2000 mg/day. RBC MCV decreased below normal during treatment in 9 patients. Nephrotoxicity was not seen. GBM progressed in 11 of 22 evaluable patients after 2 cycles and in 6 following 3—6 cycles. Three patients progressed after 8, 10, and 26 cycles. One patient with a stable partial response remains on treatment after 33 cycles. The median overall survival was 16 months. Conclusions Oral gallium maltolate is safe and well-tolerated with an RP2D of 2,000 mg/day. Further investigation to assess the clinical efficacy of gallium maltolate in GBM is warranted.
| Reference Key |
openalex_W7163914834
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jennifer M. Connelly, Casey J Zoss, Aniko Szabo, Shama P. Mirza, Frederick Adom, Lawrence R. Bernstein, Mona Al-Gizawiy, Kathleen M. Schmainda, Christopher R. Chitambar |
| Journal | Neuro-Oncology Advances |
| Year | 2026 |
| DOI |
10.1093/noajnl/vdag154
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.